JP6154809B2 - アルツハイマー病を示すマイクロｒｎａバイオマーカー - Google Patents

アルツハイマー病を示すマイクロｒｎａバイオマーカー Download PDF

Info

Publication number
JP6154809B2
JP6154809B2 JP2014518915A JP2014518915A JP6154809B2 JP 6154809 B2 JP6154809 B2 JP 6154809B2 JP 2014518915 A JP2014518915 A JP 2014518915A JP 2014518915 A JP2014518915 A JP 2014518915A JP 6154809 B2 JP6154809 B2 JP 6154809B2
Authority
JP
Japan
Prior art keywords
mir
mirna
subject
level
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014518915A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014520529A (ja
JP2014520529A5 (cg-RX-API-DMAC7.html
Inventor
ゾルタン デズソ，
ゾルタン デズソ，
パバン クマール，
パバン クマール，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2014520529A publication Critical patent/JP2014520529A/ja
Publication of JP2014520529A5 publication Critical patent/JP2014520529A5/ja
Application granted granted Critical
Publication of JP6154809B2 publication Critical patent/JP6154809B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2014518915A 2011-06-27 2012-06-26 アルツハイマー病を示すマイクロｒｎａバイオマーカー Active JP6154809B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161501720P 2011-06-27 2011-06-27
US61/501,720 2011-06-27
PCT/US2012/044202 WO2013003350A2 (en) 2011-06-27 2012-06-26 Microrna biomarkers indicative of alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016150989A Division JP2016214256A (ja) 2011-06-27 2016-08-01 アルツハイマー病を示すマイクロｒｎａバイオマーカー

Publications (3)

Publication Number Publication Date
JP2014520529A JP2014520529A (ja) 2014-08-25
JP2014520529A5 JP2014520529A5 (cg-RX-API-DMAC7.html) 2015-08-13
JP6154809B2 true JP6154809B2 (ja) 2017-06-28

Family

ID=46724591

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014518915A Active JP6154809B2 (ja) 2011-06-27 2012-06-26 アルツハイマー病を示すマイクロｒｎａバイオマーカー
JP2016150989A Pending JP2016214256A (ja) 2011-06-27 2016-08-01 アルツハイマー病を示すマイクロｒｎａバイオマーカー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016150989A Pending JP2016214256A (ja) 2011-06-27 2016-08-01 アルツハイマー病を示すマイクロｒｎａバイオマーカー

Country Status (13)

Country Link
US (1) US9771617B2 (cg-RX-API-DMAC7.html)
EP (1) EP2723894B1 (cg-RX-API-DMAC7.html)
JP (2) JP6154809B2 (cg-RX-API-DMAC7.html)
KR (1) KR102082016B1 (cg-RX-API-DMAC7.html)
CN (1) CN103781919B9 (cg-RX-API-DMAC7.html)
AU (1) AU2012275556B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013033488B8 (cg-RX-API-DMAC7.html)
CA (1) CA2840196C (cg-RX-API-DMAC7.html)
ES (1) ES2580379T3 (cg-RX-API-DMAC7.html)
IL (1) IL230034B (cg-RX-API-DMAC7.html)
MX (1) MX341840B (cg-RX-API-DMAC7.html)
RU (1) RU2639509C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013003350A2 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130040303A1 (en) * 2011-08-08 2013-02-14 Eugenia Wang Biomarker for Alzheimer's Disease and/or Mild Cognitive Impairment, and Use Thereof
WO2015050835A1 (en) * 2013-10-01 2015-04-09 Advanced Genomic Technology, Llc Circulating biomarkers for alzheimer's disease and/or mild cognitive impairment
WO2015134551A1 (en) * 2014-03-03 2015-09-11 Banyan Biomarkers, Inc. Micro rna markers for diagnosis of a neurological condition
KR101583450B1 (ko) * 2014-12-01 2016-01-11 전주대학교 산학협력단 마이크로 rna id의 분석방법 및 이를 통해 도출한 대장암의 바이오마커
US10738360B2 (en) 2015-03-13 2020-08-11 Hiroshima University Method for assisting detection of alzheimer'S disease or mild cognitive impairment
US10358676B2 (en) * 2015-04-03 2019-07-23 Kaohsiung Chang Gung Memorial Hospital Methods and kits for detecting Kawasaki disease
KR101734645B1 (ko) * 2015-05-18 2017-05-11 (주)에이엔티랩스 초기 알츠하이머 병 또는 경도 인지 장애 진단 방법
US11268965B2 (en) 2015-09-16 2022-03-08 Shimadzu Corporation Multiplex biomarker for use in evaluation of state of accumulation of amyloid B in brain, and analysis method for said evaluation
ES2734678T3 (es) * 2015-12-22 2019-12-11 Siemens Ag Firmas específicas en enfermedad de alzheimer por perfiles de miarn multicéntricos
US10262423B2 (en) * 2016-03-29 2019-04-16 Verily Life Sciences Llc Disease and fall risk assessment using depth mapping systems
WO2017186719A1 (en) * 2016-04-25 2017-11-02 Instytut Biologii Doswiadczalnej Im. Marcelego Nenckiego Polska Akademia Nauk Microrna biomarkers in blood for diagnosis of alzheimer's disease
KR101998457B1 (ko) * 2016-05-10 2019-07-10 조선대학교산학협력단 알츠하이머 질병의 진단을 위한 바이오마커
KR101992539B1 (ko) * 2016-10-21 2019-09-30 서울대학교산학협력단 miRNA 기반의 인지장애 질환 진단용 조성물 및 방법
WO2018228875A1 (en) * 2017-06-15 2018-12-20 Nestec S.A. Micro-rna biomarkers of blood-brain barrier dysfunction
ES2965473T3 (es) * 2017-06-19 2024-04-15 St Johns Univ Biomarcadores de microARN en suero circulante y métodos para el diagnóstico de la enfermedad de Alzheimer
EP3652340A4 (en) * 2017-07-12 2021-04-07 Texas Tech University System MICROARN-455-3P AS A PERIPHERAL BIOMARKER FOR ALZHEIMER'S DISEASE
US11078535B2 (en) 2017-07-18 2021-08-03 The Trustees Of Indiana University Presymptomatic micro RNA targets for treatment of neurodegeneration pathology
EP3701047A1 (en) * 2017-10-25 2020-09-02 Hummingbird Diagnostics GmbH Mirnas as biomarkers for alzheimer's disease
US20200362420A1 (en) * 2017-11-12 2020-11-19 The Regents Of The University Of California Non-coding rna for detection of cancer
EP3725882A4 (en) 2017-12-14 2022-01-05 Hiroshima University Method for aiding detection of alzheimer's disease
CN108277271A (zh) * 2018-02-05 2018-07-13 范瑶飞 一种辅助检测阿兹海默疾病的miRNA
EP4498086A3 (en) * 2018-02-13 2025-04-02 Toray Industries, Inc. Kit or device and method for detecting dementia
EP3807422B1 (en) 2018-06-15 2025-12-03 Universitat Autònoma de Barcelona Circulating mirnas as biomarkers for diagnosis of mild cognitive impairment and alzheimer´s disease
JP2021531043A (ja) * 2018-07-25 2021-11-18 スルナリティクス インコーポレイテッド アルツハイマー病に対する低分子ｒｎａ予測因子
JP6884810B2 (ja) * 2019-05-08 2021-06-09 キユーピー株式会社 情報提供装置、情報提供方法及びｍｉＲＮＡ重要度テーブル生成方法
KR20230039740A (ko) * 2020-07-24 2023-03-21 오타고 이노베이션 리미티드 인지 상태에 대한 바이오마커
WO2022165205A1 (en) * 2021-01-29 2022-08-04 Arizona Board Of Regents On Behalf Of Arizona State University Systems and methods for diagnosing neurodegenerative diseases

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5965364A (en) 1990-10-09 1999-10-12 Benner; Steven Albert Method for selecting functional deoxyribonucleotide derivatives
US5767259A (en) 1994-12-27 1998-06-16 Naxcor Oligonucleotides containing base-free linking groups with photoactivatable side chains
US5925517A (en) 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
EP0892808B1 (en) 1996-04-12 2008-05-14 PHRI Properties, Inc. Detection probes, kits and assays
SE506700C2 (sv) 1996-05-31 1998-02-02 Mikael Kubista Sond och förfaranden för analys av nukleinsyra
US6355421B1 (en) 1997-10-27 2002-03-12 Boston Probes, Inc. Methods, kits and compositions pertaining to PNA molecular beacons
US6485901B1 (en) 1997-10-27 2002-11-26 Boston Probes, Inc. Methods, kits and compositions pertaining to linear beacons
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6383752B1 (en) 1999-03-31 2002-05-07 Hybridon, Inc. Pseudo-cyclic oligonucleobases
JP5064625B2 (ja) 1999-10-27 2012-10-31 バイオウルフ テクノロジーズ エルエルスィー パターンを同定するための方法及び機械
US6528254B1 (en) 1999-10-29 2003-03-04 Stratagene Methods for detection of a target nucleic acid sequence
US6596490B2 (en) 2000-07-14 2003-07-22 Applied Gene Technologies, Inc. Nucleic acid hairpin probes and uses thereof
CN1484806A (zh) 2000-07-18 2004-03-24 �����弪��ϵͳ��˾ 基于隐含模式用于从生物数据中识别生物状态的方法
US6350580B1 (en) 2000-10-11 2002-02-26 Stratagene Methods for detection of a target nucleic acid using a probe comprising secondary structure
US7113896B2 (en) 2001-05-11 2006-09-26 Zhen Zhang System and methods for processing biological expression data
WO2003020739A2 (en) 2001-09-04 2003-03-13 Exiqon A/S Novel lna compositions and uses thereof
US6593091B2 (en) 2001-09-24 2003-07-15 Beckman Coulter, Inc. Oligonucleotide probes for detecting nucleic acids through changes in flourescence resonance energy transfer
US20020193950A1 (en) 2002-02-25 2002-12-19 Gavin Edward J. Method for analyzing mass spectra
US20030225031A1 (en) * 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
JP2004161636A (ja) 2002-11-11 2004-06-10 Takeda Chem Ind Ltd 軽度認知障害または注意欠陥多動性障害治療剤
EP2267166B1 (en) 2003-04-25 2016-01-13 Becton Dickinson and Company Detection of herpes simplex virus types 1 and 2 by nucleic acid amplification
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
EP1774025A4 (en) 2004-07-09 2009-09-16 Univ Pittsburgh IDENTIFYING MARKERS IN LUNG AND BREAST CANCER
US20060078894A1 (en) 2004-10-12 2006-04-13 Winkler Matthew M Methods and compositions for analyzing nucleic acids
JP2006176503A (ja) 2004-11-26 2006-07-06 Tohoku Univ 脳血管障害を伴うアルツハイマー病治療薬
RU2418068C2 (ru) * 2005-08-17 2011-05-10 Сирна Терапьютикс, Инк. Молекулы химически модифицированной короткой интерферирующей нуклеиновой кислоты, которые опосредуют интерференцию рнк
WO2007044937A2 (en) * 2005-10-13 2007-04-19 President And Fellows Of Harvard College Compositions and methods to modulate memory
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
BRPI0715864A2 (pt) * 2006-08-21 2013-07-30 Novartis Ag biomarcadores para progressço de doenÇa de alzheimer
WO2008153692A2 (en) * 2007-05-22 2008-12-18 The Brigham And Women's Hospital, Inc. Microrna expression profiling of cerebrospinal fluid
WO2008147839A1 (en) 2007-05-23 2008-12-04 Dharmacon, Inc. Micro-rna scaffolds and non-naturally occurring micro-rnas
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8551703B2 (en) 2007-07-06 2013-10-08 The Regents Of The University Of California SNPs associated with fatty acid composition of bovine meat and milk
WO2009009457A1 (en) * 2007-07-06 2009-01-15 University Of Louisville Research Foundation, Inc. Alzheimer's disease-specific micro-rna microarray and related methods
EP2613149B1 (en) * 2007-07-25 2014-09-17 University Of Louisville Research Foundation, Inc. Exosome-associated microRNA as a diagnostic marker
DK2195450T4 (en) 2007-08-22 2016-10-24 Trovagene Inc Methods of using miRNA FOR DETECTION IN VIVO cell death
ES2419129T3 (es) * 2007-09-14 2013-08-19 The Ohio State University Research Foundation Expresión de miARN en microvesículas de sangre periférica humana y usos del mismo
EP2261254A3 (en) 2007-12-21 2011-04-13 Amgen, Inc Anti-amyloid antibodies and uses thereof
WO2009143379A2 (en) 2008-05-21 2009-11-26 Fred Hutchinson Cancer Research Center Use of extracellular rna to measure disease
CN101386848A (zh) 2008-08-12 2009-03-18 南京大学 细胞微粒子所载微小核糖核酸及其制备研究方法和应用
EP2730662A1 (en) 2008-11-12 2014-05-14 Caris Life Sciences Luxembourg Holdings Methods and systems of using exosomes for determining phenotypes
EP2287336A1 (fr) 2009-07-31 2011-02-23 Exhonit Therapeutics SA Procédés et méthodes de diagnostic de la maladie d'Alzheimer
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
US9078914B2 (en) * 2009-09-10 2015-07-14 Velin-Pharma A/S Method for the preparation of micro-RNA and its therapeutic application
EP2496714B1 (en) 2009-11-04 2016-08-31 DiamiR, LLC Methods of using micro-rna from bodily fluids for diagnosis and monitoring of mild cognitive impairment
GB201011420D0 (en) 2010-07-06 2010-08-18 United Arab Emirates Universit Method for diagnosis
MX2013003246A (es) 2010-09-22 2013-05-22 Janssen Pharmaceutica Nv Derivados de 4, 7-dihidro-pirazolo [1, 5-a] pirazin-6-ilamina utiles como inhibidores de beta-secretasa (bace).
EP3225697A3 (en) 2010-12-30 2017-11-22 Foundation Medicine, Inc. Optimization of multigene analysis of tumor samples
US8945829B2 (en) 2011-03-22 2015-02-03 Cornell University Distinguishing benign and malignant indeterminate thyroid lesions
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment

Also Published As

Publication number Publication date
CN103781919B9 (zh) 2017-09-15
CA2840196A1 (en) 2013-01-03
JP2014520529A (ja) 2014-08-25
CN103781919B (zh) 2017-07-04
RU2639509C2 (ru) 2017-12-21
WO2013003350A2 (en) 2013-01-03
MX2013015392A (es) 2014-07-14
RU2014102357A (ru) 2015-08-10
KR102082016B1 (ko) 2020-02-26
JP2016214256A (ja) 2016-12-22
WO2013003350A3 (en) 2013-04-11
US20140378439A1 (en) 2014-12-25
KR20140044375A (ko) 2014-04-14
US9771617B2 (en) 2017-09-26
AU2012275556A1 (en) 2013-05-02
CA2840196C (en) 2022-09-20
IL230034B (en) 2021-02-28
BR112013033488B1 (pt) 2022-03-03
BR112013033488A2 (pt) 2017-03-01
MX341840B (es) 2016-09-05
EP2723894A2 (en) 2014-04-30
ES2580379T3 (es) 2016-08-23
BR112013033488B8 (pt) 2022-11-22
CN103781919A (zh) 2014-05-07
EP2723894B1 (en) 2016-05-11
AU2012275556B2 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
JP6154809B2 (ja) アルツハイマー病を示すマイクロｒｎａバイオマーカー
US20140302068A1 (en) MicroRNA Biomarkers for Diagnosing Parkinson's Disease
AU2025204881B2 (en) Non-coding RNA for detection of cancer
US11667974B2 (en) Diagnostic, prognostic and therapeutic uses of long noncoding RNAs for pathologies and toxicities inducing heart disorders
US10718018B2 (en) Complex sets of miRNAs as non-invasive biomarkers for dilated cardiomyopathy
US9631241B2 (en) Complex sets of miRNAs as non-invasive biomarkers for colon cancer
US20240150829A1 (en) System and methods of detection of oncrnas for cancer diagnosis
US20140274789A1 (en) Complex sets of mirnas as non-invasive biomarkers for psoriasis
WO2014187884A2 (en) Mirnas as non-invasive biomarkers for heart failure
US20140024554A1 (en) Complex sets of mirnas as non-invasive biomarkers for glioblastoma
AU2013204118A1 (en) MicroRNA biomarkers indicative of Alzheimer's Disease
US20250101510A1 (en) Methods and systems for sequencing polynucleotides
US20130331278A1 (en) Complex set of mirnas as non-invasive biomarkers for prostate diseases
KR20240054437A (ko) 패혈증 진단 또는 예후 예측용 신규 바이오마커 및 이의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150625

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170510

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170602

R150 Certificate of patent or registration of utility model

Ref document number: 6154809

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250